158 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
10 May 24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
7:01am
million in cash and cash equivalents plus $1.8 million in research and development incentive tax credits and $0.2 million in collaboration receivables from … quarter of 2024, compared to $0.4 million, net of $0.3 million in offsetting tax credits, for the first quarter of 2023. The increase was primarily
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
equivalents and $2.0 million in tax receivables. In February of 2024, Kiora received an additional $16 million for an upfront payment from TOI … in offsetting tax credits, compared to $3.5 million, net of $1.5 million in offsetting tax credits, for 2022. Research and development expenses
8-K
EX-10.1
u2bdz1dx3c rmebygdpn
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-4.1
19r8uu sp6ennum
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-4.3
lkbuq
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-4.2
ij40pyg
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-99.2
6b5s1
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.1
1d8kg0afjz ii0h5
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
plla5
9 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
uuk4w8ny0p2 0kcl
8 Aug 23
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
7:14am
8-K
EX-99.1
z2xwx4fakg4
1 Aug 23
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
7:00am
8-K
EX-1.1
bqmef0qtjn
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm